Our share position has held strong as we’ve seen the entrance of new competition within the class. In the second-line setting, as I mentioned in my prepared remarks, we have seen erosion of our share in that relapsed/refractory setting, particularly within the naive. We remain, as we see it, still the leaders within this space. That said, it is a pretty tight share split among the three players as we see it within that space. In terms of now switching to the commercial opportunity for TROPION-Breast01, I think that maybe the primary thing that I’d lay out here is that I think what we’re really seeking on this is category leadership with in breast cancer. I think that as you quite rightly point out, across the G7 countries, there are a large number, over 35,000 fourth line and beyond patients treated across the G7 in hormone receptor positive and HER2-negative disease.
And I think that what we’ll really be looking to do is understanding how patient selection and sequencing can create opportunities both for in HER2 as well as for Dato-DX. And I think that an important part of the approach that we’re taking is to try to have an AstraZeneca medicine that is appropriate for patients with various different subtypes. And also in various different sequence over time. And I think that I would look at the opportunity to replace chemotherapy across late-line breast cancer as a category is how we’re thinking about the portfolio of medicines.
Susan Galbraith: And so to answer the question about biomarker development for Dato-DX — so in principle, antibody-drug conjugates are targeted medicines. And I think as a general principle, we want biomarkers to identify the right patients for targeted medicines across that class. And so as we’ve indicated, we are working on a biomarker for the TROP2 program, and we will use the data that we’ve got from TLO 1, to help with that effort, and we can update you on that once the analyses are completed. I think your comment about retrospective versus prospective. Obviously, in an ideal world, you want prospective selection in order to make sure that you’ve got a balance you often stratify for that presence in such trials, but there are multiple examples of retrospective analysis based on the prospect of definition of that have enabled an approval in that setting.
Pascal Soriot: The next question is from Gonzalo Artiach with ABG. Go ahead Gonzalo
Gonzalo Artiach: Clear..
Pascal Soriot: Yes, we can hear you, go ahead. We can’t hear you. So let’s move to the next…
Gonzalo Artiach: Yes. Now can you hear me?
Gonzalo Artiach: Yes. Gonzalo, go ahead. We can hear you now.
Gonzalo Artiach: Okay, great. So first one, it’s regarding your yesterday’s news on DESTINY-Pantumor02. And with the data presented yesterday, improved PFS and OS in line with what you showed at ASCO. How much does this help for a potential tumor-agnostic approval? And here, what is your view on this debate of the use of HER2 grades of an expression levels as the market for potential treatment approach? And specifically in IHC 3+, where did you — you didn’t see any major improvements in terms of ORR, but could you share anything on how does this new parameters PFS and OS look like? Thank you.
Susan Galbraith: Okay. Thank you for the question. So as we shared at ASCO, what we’ve seen with NHAI in the Pantumor02 study is impressive response rate and durability of response across multiple tumor types, particularly impressive in the gynecologic cancers of endometrial cancer, ovarian and cervical but also encouraging data across multiple other tumors. And of course, what we saw in that study with an enhanced response rate in the IHC 3+ compared with the IHC 2+ populations. So it’s important just to remember that there’s a mix nature in this trial, you’ve got multiple different genotypes with different lines of therapy, but generally heavily pretreated patient population. And what you saw there was a response durability response, which is beyond what you would readily expect and certainly in the IHC3+ population for a standard of care chemotherapy in that setting.
